Merck's Non-Oncology Drugs Q3 Performance: What to Expect

Key Takeaways MRK will report Q3 results on Oct. 30, with investors watching the performance of key non-oncology drugs.Capvaxive and Winrevair saw strong early uptake, boosting MRK's non-oncology growth outlook.Animal Health growth and new drug launches are likely to support second-half revenues.Merck (MRK) is scheduled to report third-quarter 2025 results on Oct. 30. Investors are likely to focus on the sales performance of its blockbuster cancer drug, Keytruda. The drug accounted for more than 50% of the ...